Real-World Clinical Effectiveness of Liraglutide for Weight Management in Türkiye: Insights from the LIRA-TR Study

Overview

Journal J Clin Med

Specialty General Medicine

Date 2024 Oct 26

PMID 39458071

Authors

Alihan Oral

Celalettin Kucuk

Murat Kose

Affiliations

Soon will be listed here.

Abstract

Obesity is a complicated chronic disease associated with a series of other conditions. A weight loss of 5-10% has been shown to reduce obesity-related complications and improve quality of life. The efficacy and safety of liraglutide for reducing body weight have been demonstrated in clinical trials. This study evaluated the weight loss efficacy and adverse effects of liraglutide in those with obesity in the Turkish population. This is a retrospective cohort study; the patients that were included had a body mass index (BMI) of 27 or greater with additional comorbidities or a BMI of 30 or greater, and the patients were prescribed liraglutide for obesity treatment from the tertiary private clinic between January 2022 and January 2024. Their metabolic and anthropometric parameters were recorded at the initial appointment, and their body weight and adverse effects were followed up on during therapy. For the 568 patients, of whom 487 (85.6%) were female, the mean values for age, weight, and BMI were 42.37 ± 10.50, 98.09 ± 17.48 kg, and 35.77 ± 5.45 kg/m, respectively. Reductions in body weight at the 4th, 8th, 12th, and 24th weeks were 6.45 ± 2.32 kg, 10.66 ± 3.41 kg, 15.38 ± 8.30 kg, and 19 ± 9.06 kg, respectively; reductions in BMI at the 4th, 8th, 12th, and 24th weeks were 2.36 ± 1.00, 3.88 ± 1.25, 5.36 ± 1.76, and 7.09 ± 2.93, respectively; and the percentages of overall body weight loss at the 4th, 8th, 12th, and 24th weeks were 6.62 ± 2.1%, 10.75 ± 2.71%, 14.97 ± 6.8%, and 18.55 ± 4.63%, respectively (all values < 0.0001). The percentage of patients who lost more than 5% and more than 10% of their initial weight was 100% at the 24th week. The most common side effect was nausea; no pancreatitis was observed. The results of our study indicate that liraglutide is an efficacious and safe treatment option for obesity in the Turkish population, in accordance with the findings from previous research.

References

Lau D, Douketis J, Morrison K, Hramiak I, Sharma A, Ur E . 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. CMAJ. 2007; 176(8):S1-13. PMC: 1839777. DOI: 10.1503/cmaj.061409. View

Wadden T, Hollander P, Klein S, Niswender K, Woo V, Hale P . Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 2013; 37(11):1443-51. DOI: 10.1038/ijo.2013.120. View

Schultes B, Timper K, Cavadini G, Ruh J, Gerber P . Weight loss and treatment patterns in a real-world population of adults receiving liraglutide 3.0 mg for weight management in routine clinical practice in Switzerland (ADDRESS study). Diabetes Obes Metab. 2023; 26(3):1023-1032. DOI: 10.1111/dom.15403. View

Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M . A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015; 373(1):11-22. DOI: 10.1056/NEJMoa1411892. View

Cetiner S . A single-center study on the biochemical effect and clinical effectiveness of liraglutide in Turkish patients. Eur Rev Med Pharmacol Sci. 2023; 27(18):8740-8753. DOI: 10.26355/eurrev_202309_33796. View

Poobalan A, Aucott L, Smith W, Avenell A, Jung R, Broom J . Long-term weight loss effects on all cause mortality in overweight/obese populations. Obes Rev. 2007; 8(6):503-13. DOI: 10.1111/j.1467-789X.2007.00393.x. View

Davies M, Bergenstal R, Bode B, Kushner R, Lewin A, Skjoth T . Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA. 2015; 314(7):687-99. DOI: 10.1001/jama.2015.9676. View

van Can J, Sloth B, Jensen C, Flint A, Blaak E, Saris W . Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond). 2013; 38(6):784-93. PMC: 4052428. DOI: 10.1038/ijo.2013.162. View

Park J, Kwon J, Choi H, Lee C . Clinical effectiveness of liraglutide on weight loss in South Koreans: First real-world retrospective data on Saxenda in Asia. Medicine (Baltimore). 2021; 100(2):e23780. PMC: 7808520. DOI: 10.1097/MD.0000000000023780. View

10.

Blackman A, Foster G, Zammit G, Rosenberg R, Aronne L, Wadden T . Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes (Lond). 2016; 40(8):1310-9. PMC: 4973216. DOI: 10.1038/ijo.2016.52. View

11.

Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean M . Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond). 2011; 36(6):843-54. PMC: 3374073. DOI: 10.1038/ijo.2011.158. View

12.

Alonso-Troncoso I, Carollo-Limeres C, Rios-Prego M, Guler I, Cadarso-Suarez C, F-Marino A . Liraglutide in a real-world setting: Joint modeling of metabolic response, prediction of efficacy, and cardiovascular risk. Endocrinol Diabetes Nutr (Engl Ed). 2018; 66(6):376-384. DOI: 10.1016/j.endinu.2018.09.005. View

13.

Lin K, Schneeweiss S . Considerations for the analysis of longitudinal electronic health records linked to claims data to study the effectiveness and safety of drugs. Clin Pharmacol Ther. 2016; 100(2):147-59. DOI: 10.1002/cpt.359. View

14.

Knudsen L . Liraglutide: the therapeutic promise from animal models. Int J Clin Pract Suppl. 2010; (167):4-11. DOI: 10.1111/j.1742-1241.2010.02499.x. View

15.

Durrer Schutz D, Busetto L, Dicker D, Farpour-Lambert N, Pryke R, Toplak H . European Practical and Patient-Centred Guidelines for Adult Obesity Management in Primary Care. Obes Facts. 2019; 12(1):40-66. PMC: 6465693. DOI: 10.1159/000496183. View

16.

Polidori D, Sanghvi A, Seeley R, Hall K . How Strongly Does Appetite Counter Weight Loss? Quantification of the Feedback Control of Human Energy Intake. Obesity (Silver Spring). 2016; 24(11):2289-2295. PMC: 5108589. DOI: 10.1002/oby.21653. View

17.

Wharton S, Liu A, Pakseresht A, Nortoft E, Haase C, Mancini J . Real-World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada. Obesity (Silver Spring). 2019; 27(6):917-924. PMC: 6593982. DOI: 10.1002/oby.22462. View

18.

Yumuk V, Tsigos C, Fried M, Schindler K, Busetto L, Micic D . European Guidelines for Obesity Management in Adults. Obes Facts. 2015; 8(6):402-24. PMC: 5644856. DOI: 10.1159/000442721. View

19.

Gadde K, Martin C, Berthoud H, Heymsfield S . Obesity: Pathophysiology and Management. J Am Coll Cardiol. 2018; 71(1):69-84. PMC: 7958889. DOI: 10.1016/j.jacc.2017.11.011. View

20.

Papamargaritis D, Al-Najim W, Lim J, Crane J, Lean M, Le Roux C . Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial. BMJ Open. 2020; 10(2):e034137. PMC: 7044994. DOI: 10.1136/bmjopen-2019-034137. View